#United States #Lexington #Piramal Pharma #ADCelerate #Riverview Kentucky

Piramal Pharma Solutions Initiates Major Expansion

Piramal Pharma Solutions, a prominent player in the pharmaceutical manufacturing sector, has taken a bold step in the expansion of its capabilities by investing $90 million to enhance two of its key facilities located in the United States. This strategic decision marks a significant milestone not only for Piramal Pharma but also for the broader healthcare landscape, particularly in the area of drug development and manufacturing.

On June 25, 2025, the groundbreaking ceremony for the expansion of the company's sterile injectables development and manufacturing facility was held, signaling the start of construction and the future growth potential of the business. This ambitious expansion is set to bolster Piramal Pharma's integrated antibody-drug conjugate (ADC) offering known as ADCelerate™, enhancing the company's ability to deliver innovative medical solutions tailored to patient needs.

The facilities earmarked for this expansion include one in Riverview, Michigan, which specializes in drug substance development and manufacturing. This site plays a crucial role in providing specialized solutions for high potency APIs (HPAPIs), which are essential for ensuring the efficacy and safety of ADC therapies. As part of the expansion, a commercial-scale suite dedicated to manufacturing payload-linkers will be established, expected to commence operations by the end of 2025.

The second facility being expanded is located in Lexington, Kentucky, known for its focus on sterile compounding and the fill/finish process for injectable drug products. The expansion here will encompass an additional 24,000 square feet of manufacturing space, thereby significantly enhancing its capability to produce sterile injectables. This facility will be equipped with modern machinery, including a new filling line and commercial-size lyophilizers, set to be operational by late 2027. The growth in this facility is not only expected to double its manufacturing output but also create 40 new full-time jobs, contributing to the local economy.

The timing of this investment comes at a crucial moment, as the sterile injectables market is witnessing remarkable growth driven by increased medical needs and regulatory approvals. Furthermore, advancements in scientific research have made sterile injectables an attractive solution among healthcare providers and patients alike. Similarly, the ADC market is rapidly evolving, with significant demand for innovative therapies that target specific cancers and diseases. Piramal's expansion positions the company to meet these emergent trends effectively and efficiently, enhancing its competitive positioning in the global market.

In her remarks regarding the investment, Nandini Piramal, Chairperson of Piramal Pharma, emphasized the company's commitment to understanding and addressing the needs of its patients and clients. She pointed out that the sterile injectables market is anticipated to exceed $20 billion by 2028, reinforcing the necessity for enhanced manufacturing offerings in this segment.

Peter DeYoung, CEO of Piramal Global Pharma, also acknowledged that the evolution of market preferences necessitates adaptability and innovative solutions. He highlighted the importance of expanding the Lexington and Riverview facilities as key to enhancing the integrated ADC offering and meeting the increasing demand for high-quality, innovative treatments.

At the groundbreaking event, notable figures expressed their enthusiasm for the project. Lexington Mayor Linda Gorton stated that Piramal’s decision to expand in Lexington signifies the city's potential as a business hub, with strengths in life sciences and pharmacy education led by the University of Kentucky College of Pharmacy. Other community leaders echoed this sentiment, noting the area's growth in the biotech and life sciences sectors.

In summary, Piramal Pharma Solutions' $90 million investment highlights its dedication to growth and innovation in the pharmaceutical manufacturing domain. This expansion not only aims to meet the rising demand for sterile injectables and ADC therapies but also reinforces the company's commitment to delivering comprehensive and patient-centric healthcare solutions. This strategic move positions Piramal Pharma to play an essential role in the future landscape of pharmaceuticals, benefiting patients and healthcare providers worldwide.

For more information on their developments and offerings, visit Piramal Pharma Solutions online.